Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill
This article is for subscribers only.
Bristol-Myers Squibb Co. will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc.’s approved pill.
Bristol-Myers and Gilead are among several companies developing hepatitis C therapies that rely on combinations of two or more drugs. Those regimens are being approved by regulators one drug at a time for a hepatitis C market analysts estimate may reach $100 billion over a decade.